Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150965 · ClinicalTrials.gov registry record · Phase 1
Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT
A Phase 1 study, sponsored by Multiple Myeloma Research Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT04150965 is a Phase 1 study that was terminated before completion, run by Multiple Myeloma Research Consortium. The registered enrollment target is 14 participants.
The verdict
NCT04150965, a Phase 1 study, was terminated before completion, sponsored by Multiple Myeloma Research Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single agents and in combination with pomalidomide and dexamethasone. In these arms, patients will be treated with either Anti-LAG-3 or Anti-TIGIT respectively for one cycle as single agent followed by the addition of pomalidomide and dexamethasone in combination for subsequent cycles. A third arm allows patients to be treated with the FDA approved combination of elotuzumab plus pomalidomide and dexamethsone as a control. This arm will thus allow a concurrent standard of care comparator for the experimental arms.
Interventions
- DRUG Elotuzumab, pomalidomide, dexamethasone
- DRUG Anti-LAG-3
- DRUG Anti-LAG-3 + Pomalidimide + Dexamethasone
- DRUG Anti-TIGIT
- DRUG Anti-TIGIT + Pomalidimide + Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-07-10 |
| Est. Completion | 2024-08-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150965
The ClinicalTrials.gov registry entry for NCT04150965 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Multiple Myeloma Research Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Elotuzumab, pomalidomide, dexamethasone is the first listed.
NCT04150965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04150965 about?
NCT04150965 is a clinical study titled "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT". This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their immunologic effects and safety both as single age...
What is the current status of trial NCT04150965?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2020-07-10. Estimated completion is 2024-08-30.
What interventions are being tested in trial NCT04150965?
The interventions under investigation include: Elotuzumab, pomalidomide, dexamethasone (DRUG), Anti-LAG-3 (DRUG), Anti-LAG-3 + Pomalidimide + Dexamethasone (DRUG), Anti-TIGIT (DRUG), Anti-TIGIT + Pomalidimide + Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT04150965?
This trial is sponsored by Multiple Myeloma Research Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.